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INTRODUCTION
Liver fibrosis represents the wound healing response to
chronic liver injury brought about by processes such as chron-
ic viral hepatitis, excessive alcohol consumption, nonalcoholic
steatohepatitis, hemochromatosis, or immune-mediated liver
injury (1). Cirrhosis develops if liver fibrosis progresses. Cir-
rhosis is characterized by the presence of bands of fibrosis,
parenchymal nodules, and vascular distortion, all of which
lead to hepatic dysfunction and the major life-threatening
complications that characterize the condition.
Therefore, an accurate assessment of disease severity is im-
portant in predicting prognosis and guiding treatment deci-
sions in patients with chronic liver disease. Liver biopsy is
still considered the gold standard for assessing liver fibrosis
(2). This procedure is very useful because it provides informa-
tion about the degree of liver fibrosis, as well as the severity
and extent of inflammation (2). However, it is invasive and
can lead to grave complications (3, 4). Furthermore, its accu-
racy in assessing fibrosis is questionable because of sampling
errors (5-9) and intra- and inter-observer discrepancies (9-11).
In addition, because liver biopsy is a static examination, it
does not represent the dynamic changes during the progres-
sion of liver fibrosis.
To circumvent the limitations of liver biopsy, noninvasive
markers have attracted the attention of many investigators,
and various markers in the blood have been proposed as poten-
tial indicators of liver fibrosis. Some studies have suggested
the fibrosis-predicting models composed of several potential
blood markers, including AAR (AST/ALT ratio) (12-14), PGA
(prothrombin time, g-GT, apolipoprotein A1), PGAA index
(prothrombin time, g-GT, apolipoprotein A1, a2-macroglobu-
lin), FibroTest
�(15), Forns fibrosis index (FFI) (16), and age to
platelet ratio index (APRI) (17). Other reports have suggested
several serum markers, including collagen, hyaluronic acid,
YKL-40, matrix metalloproteinase (MMP), and tissue inhi-
bitor of metalloproteinase (TIMP), all of which have a poten-
tial role in the accumulation or degradation of extracellular
matrix (ECM) (18, 19). However, comprehensive validating
studies dealing with all these blood markers simultaneously
in a large group of patients have rarely been carried out, par-
ticularly in the area where hepatitis B virus is endemic.
67
Han Hyo Lee
1, Yeon Seok Seo
1, 
Soon Ho Um
1, Nam Hee Won
2, 
Hanna Yoo
3, Eun Suk Jung
1, 
Yong Dae Kwon
1, Sanghoon Park
1, 
Bora Keum
1, Yong Sik Kim
1, 
Hyung Joon Yim
1, Yoon Tae Jeen
1, 
Hoon Jai Chun
1, Chang Duck Kim
1, 
and Ho Sang Ryu
1
Departments of Internal Medicine
1, and Pathology
2,
College of Medicine; Department of Statistics
3, Korea 
University, Seoul, Korea
Address for Correspondence
Soon Ho Um, M.D.
Department of Internal Medicine, Korea University 
College of Medicine, 73 Inchon-ro, Seongbuk-gu,
Seoul 136-705, Korea
Tel : +82.2-920-5019, Fax : +82.2-953-1943
E-mail : umsh@korea.ac.kr
This study was supported by a grant from Ministry for
Health, Welfare and Family Affairs, Republic of Korea
(No. A050021).
J Korean Med Sci 2010; 25: 67-74 ISSN 1011-8934
DOI: 10.3346/jkms.2010.25.1.67
Usefulness of Non-invasive Markers for Predicting Significant Fibrosis
in Patients with Chronic Liver Disease
The purpose of this prospective study was to verify and compare the strengths of
various blood markers and fibrosis models in predicting significant liver fibrosis. One
hundred fifty-eight patients with chronic liver disease who underwent liver biopsy
were enrolled. The mean age was 41 yr and male patients accounted for 70.2%.
The common causes of liver disease were hepatitis B (67.7%) and C (16.5%) and
fatty liver (9.5%). Stages of liver fibrosis (F0-4) were assessed according to the Batts
and Ludwig scoring system. Significant fibrosis was defined as ≥F2. Sixteen blood
markers were measured along with liver biopsy, and estimates of hepatic fibrosis
were calculated using various predictive models. Predictive accuracy was evaluat-
ed with a receiver-operating characteristics (ROC) curve. Liver biopsy revealed sig-
nificant fibrosis in 106 cases (67.1%). On multivariate analysis, a2-macroglobulin,
hyaluronic acid, and haptoglobin were found to be independently related to signifi-
cant hepatic fibrosis. A new predictive model was constructed based on these vari-
ables, and its area under the ROC curve was 0.91 (95% confidence interval, 0.85-
0.96). In conclusion, a2-macroglobulin, hyaluronic acid, and haptoglobin levels are
independent predictors for significant hepatic fibrosis in chronic liver disease. 
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Received : 20 October 2008
Accepted : 15 February 2009This study was performed prospectively in order to assess
and compare the predictive power of a variety of previously-
reported surrogate markers for identifying significant fibro-
sis, and preferably, to establish a more reliable predictive model
for liver fibrosis.
MATERIALS AND METHODS
Patients
All consecutive patients with chronic liver disease seen in
our institution between June 2006 and December 2007 with
an indication for percutaneous liver biopsy were included in
this study. Liver biopsy was performed for assessment of the
severity of liver fibrosis and inflammation prior to treatment
or for the evaluation of the cause of liver disease. 
The cause of chronic liver disease was determined using
standard diagnostic criteria. Chronic hepatitis B was diag-
nosed by positive serologic tests for serum hepatitis B surface
antigen for at least 6 months. Chronic hepatitis C was diag-
nosed by serologic detection of hepatitis C antibody and posi-
tive serum hepatitis C virus RNA by polymerase chain reac-
tion. Alcoholic liver disease was diagnosed in patients with
consumption of at least 80 g of alcohol daily for more than
five years without other causes of chronic liver diseases. The
diagnosis of nonalcoholic fatty liver disease was in patients
with elevated aminotransferses and liver histology showing
steatosis in at least 10% of hepatocytes without causes of
chronic liver diseases. Primary biliary cirrhosis was diagnos-
ed by at least two of the following criteria: serum alkaline
phosphatase more than 1.5 times the upper limit of normal,
positive antimitochondrial antibody, and compatible liver
histology. The diagnosis of autoimmune hepatitis was based
on the revised descriptive criteria reported by the Internation-
al Autoimmune Hepatitis Group. Patients were excluded
from the study if they had any disorder associated with extra-
hepatic fibrosis, including rheumatic, renal, or lung disease;
any cardiovascular disease or cancer; or advanced cirrhosis with
evidence of decompensation. Weight and height on the liver
biopsy day and average alcohol consumption during the 5
preceding years were recorded for each patient. 
All patients provided written informed consent for their
participation in the study, and the conditions of the consent
were in strict adherence to the principles of the Declaration
of Helsinki.
Surrogate markers for fibrosis
Laboratory tests, including platelet count, prothrombin
time, alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), alkaline phosphatase (ALP), and g-glutamyl-
transpeptidase (g-GT), were evaluated in all patients on the
liver biopsy day, using commercially available assays. Apoli-
poprotein A1 (Roche, Munich, Germany), a2-macroglobu-
lin (Dade Behring, Marburg, Germany), haptoglobin (Roche,
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AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; INR, international normalized ratio; g-GT, gamma-glutamyl
transpeptidase; AAR, AST/ALT ratio; FFI, Forns fibrosis index; APRI, AST-to-platelet ratio index; ULN, upper limit of normal; API, age-platelet index;
CDS, cirrhosis discriminant score.
Panels Components
AAR AST/ALT
PGA index 1. PT (% of control): ≥80=0; 70-79=1; 60-69=2; 50-59=3; <50=4
2. g-GT (IU/L): <20=0: 20-49=1; 50-99=2; 100-199=3; ≥200=4
3. Apolipoprotein A1 (mg/dL): ≥200=0; 175-199=1; 150-174=2; 125-149=3; <125=4
PGA index is the sum of the above.
PGAA index 1. PT (% of control): ≥80=0; 70-79=1; 60-69=2; 50-59=3; <50=4
2. g-GT (IU/L): <20=0: 20-49=1; 50-99=2; 100-199=3; ≥200=4
3. Apolipoprotein A1 (mg/dL): ≥200=0; 175-199=1; 150-174=2; 125-149=3; <125=4
4. a2-macroglobulin (g/L): <1.25=0; 1.25-1.74=1; 1.75-2.24=2; 2.25-2.74=3; ≥2.75=4
PGAA index is the sum of the above.
FFI FFI=7.811-3.131×ln (platelet count [×10
9/L]) + 0.781×ln (g-GT [IU/L])+ 3.467×ln (age [years])-0.014ln 
(cholesterol [mg/dL])
APRI APRI=(AST/ULN)/platelet[×10
9/L])×100
API 1. Age (years): <30=0; 30-39=1; 40-49=2; 50-59=3; 60-69=4; ≥70=5
2. Platelet count (×10
9/L): ≥225=0; 200-224 =1; 175-199=2; 150-174=3; 125-149=4; <125=5
AP index is the sum of the above.
CDS 1. Platelet count (×10
9/L): >340=0; 280-339 =1; 220-279=2; 160-219=3; 100-159=4; 40-99=5; <40=6
2. ALT/AST ratio: >1.7=0; 1.2-1.7=1; 0.6-1.19=2; <0.6=3
3. PT INR: <1.1=0; 1.1-1.4=1; >1.4=2
CDS is the sum of the above.
Table 1. Various predictive models for liver fibrosis in patients with chronic liver diseaseMunich, Germany), collagen IV (Fine chemical, Tokyo, Japan),
and hyaluronic acid (Corgenix, Denver, CO, USA) were deter-
mined in serum samples using an enzyme immunoassay. The
procollagen III N-terminal peptide (PIIINP) concentration
was measured using a radioimmunoassay (Orion Diagnostica,
Espoo, Finland). A sandwich immunoassay was used to quan-
tify serum YKL-40 (Metra Biosystems/Quidel, San Diego,
CA, USA), matrix metalloproteinases (MMP)-2 and -9 (R &
D Systems, Minneapolis, MN, USA), and tissue inhibitor of
metalloproteinase (TIMP)-1 (R & D Systems). In addition,
using the results of surrogate markers, various well-known
predictive models for fibrosis, including the AST/ALT ratio
(AAR) (20), PGA index (prothrombin time, g-GT, apolipo-
protein A1) (21), PGAA index (prothrombin time, g-GT,
apolipoprotein A1, a2-macroglobulin) (1), Forns fibrosis
index (FFI; platelet count, g-GT, age, cholesterol) (16), AST
to platelet ratio index (APRI) (17), age platelet index (API)
(22), and cirrhosis discriminant score (CDS; platelet count,
AST, ALT, PT INR) (23), were calculated using the equa-
tions in Table 1.
Liver histology
Liver biopsies were carried out by ultrasound-guided tech-
nique using a 16-gauge biopsy needle, and the total length
of the biopsy specimen was more than 1.5 cm. Liver biopsy
sections were formalin-fixed, paraffin-embedded, and stained
routinely with hematoxylin-eosin-saffron and Masson’s tri-
chrome. All liver biopsies were evaluated blindly, and the
histological changes of chronic hepatitis were classified accord-
ing to the Batts and Ludwig scoring system (24) by a single
experienced pathologist blinded to both clinical data and the
results of noninvasive tests. Fibrosis was staged on a 0-4 scale
as follows: F0, no fibrosis; F1, fibrous portal expansion; F2,
periportal fibrosis with periportal or rare portal-portal septa;
F3, fibrous septa with architectural distortion but no obvious
cirrhosis; F4, cirrhosis. Fibrosis was considered significant
when the fibrosis stage was F2 or more. 
Statistical analysis
All data were analyzed using SPSS statistical package soft-
ware version 13.0 (SPSS Inc., Chicago, IL, USA). Data are
presented as mean±SD. Student t-test and the chi-square
test were used to compare quantitative and qualitative vari-
ables, respectively. Patients were categorized according to the
severity of their histologic lesions. The relationship between
fibrosis stage and other variables was assessed using Spear-
man’s correlation analysis. Logistic regression analysis with
a stepwise forward approach was used to determine indepen-
dent predictive markers for significant fibrosis among the var-
ious markers. In addition, a new predictive model was con-
structed by modeling the values of the independent variables
and their coefficients of regression. The predictive accuracy
was assessed by calculating the area under the receiver-oper-
ating characteristics curve (AUROC). AUROCs were com-
pared using the method of Hanley and McNeil (25). A two-
tailed P value less than 0.05 was considered statistically sig-
nificant.
RESULTS
Patient characteristics
One hundred fifty-eight patients with chronic liver disease
were enrolled in this study. Their demographic and baseline
characteristics are summarized in Table 2. There were 111 men
and 47 women, and their mean age was 41±13 yr. Causes
of chronic liver disease included chronic hepatitis B in 107
patients (67.7%), chronic hepatitis C in 26 (16.5%), nonal-
coholic fatty liver disease in 15 (9.5%), alcoholic liver disease
in 3 (1.9%), autoimmune hepatitis in 3 (1.9%), primary bil-
iary cirrhosis in 2 (1.3%), and cryptogenic cirrhosis in 2 (1.3
%). The fibrosis stages identified on liver biopsy was F0 in
18 patients (11.4%), F1 in 34 (21.5%), F2 in 41 (25.9%),
F3 in 41 (25.9%), and F4 in 24 (15.2%). A total of 106 pati-
ents (67.1%) had significant fibrosis (≥F2).
Correlations between surrogate markers and stage of
liver fibrosis
The results of various markers according to fibrosis stage
are presented in Fig. 1, and the correlation between various
clinical variables and fibrosis stage are shown in Table 3. Pla-
telet count, prothrombin time, and haptoglobin and MMP-9
levels showed a negative correlation with fibrosis stage (P<
0.01), whereas the levels of procollagen III, collagen IV, hya-
luronic acid, a2-macroglobulin, MMP-2, TIMP-1, and YKL-
40 showed a positive correlation (P<0.01).
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BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; g-GT, gamma-glutamyl transpeptidase; PT, prothrom-
bin time.
Characteristics Mean±SD
Gender (male:female) 111:49
Age (yr) 41±13
BMI (kg/m
2) 23.9±3.4
Platelet (×10
3/mL) 185±72
AST (IU/L) 102±169
ALT (IU/L) 145±229
Albumin (g/dL) 4.2±0.6
Bilirubin (mg/dL) 0.9±0.8
g-GT (IU/L) 95±143
PT (%) 96±21
Table 2. Baseline characteristics of patients (n=158)The efficacy of various surrogate markers for predicting
significant liver fibrosis 
Of 12 single surrogate markers, the AUROCs of hyaluron-
ic acid, haptoglobin, collagen IV, and a2-macroglobulin were
above 0.75 (0.81, 0.79, 0.77, and 0.75, respectively) for pre-
dicting F≥2 in all enrolled patients. The AUROC of hya-
luronic acid was significantly higher than those of platelet
count, prothrombin time, PIIINP, MMP-2, MMP-9, TIMP-
1, YKL-40, and apolipoprotein A1 (Table 4). Of the previ-
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A
Fig. 1. Box plots of each marker of fibrosis according to the stage of liver fibrosis. The top and bottom of each box are the 25th and 75th
percentiles, giving the interquartile range. The line through the middle of each box represents the median. The error bars are the 5th and
95th percentiles. 
PIIINP, procollagen III N-terminal peptide; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase.
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YKL-40ously reported fibrosis prediction models, the AUROCs of
the PGAA index, FFI, APRI, and API were above 0.75 (0.75,
0.79, 0.76, and 0.77, respectively) for predicting F≥2. How-
ever, the AUROCs of these predictive models were not sig-
nificantly superior to those of single surrogate markers (Table
4). Subgroup analysis was performed in patients with chron-
ic hepatitis B to exclude the effect of liver disease etiology,
and the results were found to be similar to those seen in the
whole series (Table 4). Briefly, hyaluronic acid, collagen IV,
PGAA, FFI, APRI, and API were useful for the prediction
of F≥2 (AUROCs: 0.80, 0.75, 0.81, 0.83, 0.76, and 0.77,
respectively).
Uni- and multi-variate analyses for determining factors
associated with significant fibrosis (≥F2) 
The results of univariate analysis for predicting liver fibro-
sis stage ≥F2 are represented in Table 5. The markers show-
ing a significant association with fibrosis stages F2-F4 were
age (P<0.001); platelet and PT (P<0.05); ALT, AST, and GGT
(P<0.01); haptoglobin, MMP-9, hyaluronic acid, a2-macro-
globulin, MMP-9, TIMP-1, and YKL-40 (P<0.001). On
multivariate analysis, hyaluronic acid, a2-macroglobulin, and
haptoglobin were independent predictive factors associated
with significant fibrosis (≥F2) (Table 6).
Establishment of a new predictive model for detecting
significant fibrosis (F≥2)
In order to establish a predictive model for detecting sig-
nificant liver fibrosis, the independent predictive factors that
were significant on multivariate analysis, including hyaluron-
ic acid, a2-macroglobulin, and haptoglobin, were categorized
into three groups according to their values. By providing ade-
quate scores to each category of each factor in consideration
of their respective predictive strengths on multivariate anal-
ysis, we were able to establish a new predictive model for sig-
nificant liver fibrosis, the AHH index (Table 7). AHH score
is calculated by the sum of the scores of three variables.
The scores were significantly different between patients with
F0-1 (3.2±1.8) and those with F2-4 (6.7±1.8; P<0.001)
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AST, aspartate aminotransferase; ALT, alanine aminotransferase; g-GT,
gamma-glutamyl transpeptidase; MMP, matrix metalloproteinase; PIIINP,
procollagen III N-terminal peptide; TIMP, tissue inhibitor of metallopro-
teinase; AAR, AST/ALT ratio; PGA composed of prothrombin time (PT),
g-GT, and apolipoprotein A1; PGAA composed of PT, g-GT, apolipopro-
tein A1, and a2-macroglobulin; FFI (Forns fibrosis index) composed of
platelet count, g-GT, age, and cholesterol; APRI, AST-to-platelet ratio
index; API, age platelet index; CDS (cirrhosis discriminant score) com-
posed of platelet count, AST, ALT, PT INR. 
Fibrosis score
vs.
Bivariate Spearman’s rank
correlation coefficient
P value
Age (yr) 0.38 <0.001
Platelet count (×10
3/mL) -0.46 <0.001
Prothrombin time (%) -0.42 <0.001
AST (IU/L) 0.17 NS
ALT (IU/L) -0.06 NS
g-GT (IU/L) 0.13 NS
Cholesterol (mg/dL) -0.15 NS
Apolipoprotein A1 (mg/dL) 0.002 NS
PIIINP (U/mL ) 0.29 0.001
Haptoglobin (mg/dL) -0.50 <0.001
Collagen IV (ng/mL) 0.55 <0.001
Hyaluronic acid (ng/mL) 0.56 <0.001
a2-macroglobulin (mg/dL) 0.45 <0.001
MMP-2 (ng/mL) 0.43 <0.001
MMP-9 (ng/mL) -0.39 <0.001
TIMP-1 (ng/mL) 0.22 0.006
YKL-40 (ng/mL) 0.42 <0.001
AAR 0.33 <0.001
PGA index 0.15 NS
PGAA index 0.37 <0.001
FFI 0.55 <0.001
APRI 0.36 <0.001
CDS 0.24 0.002
API 0.52 <0.001
Table 3. Correlations between various clinical variables and
stage of liver fibrosis
AUROC, area under the receiver-operating characteristics curve; CI,
confidence interval; AST, aspartate aminotransferase; ALT, alanine amino-
transferase; g-GT, gamma-glutamyl transpeptidase; MMP, matrix met-
alloproteinase; PIIINP, procollagen III N-terminal peptide; TIMP, tissue
inhibitor of metalloproteinase; AAR, AST/ALT ratio; PGA composed of
prothrombin time (PT), g-GT, and apolipoprotein A1; PGAA composed
of PT, g-GT, apolipoprotein A1, and a2-macroglobulin; FFI (Forns fibro-
sis index) composed of platelet count, g-GT, age, and cholesterol; APRI,
AST-to-platelet ratio index; API, age platelet index; CDS (cirrhosis dis-
criminant score) composed of platelet count, AST, ALT, PT INR.
In the whole 
series of patients
Markers
In patients with 
chronic hepatitis B
Platelet 0.72 (0.64-0.80) 0.70 (0.59-0.81)
Prothrombin time 0.67 (0.58-0.76) 0.66 (0.54-0.78)
Haptoglobin 0.79 (0.72-0.87) 0.73 (0.62-0.84)
a2-macroglobulin 0.75 (0.67-0.83) 0.70 (0.58-0.81)
Apolipoprotein A1 0.54 (0.44-0.64) 0.37 (0.25-0.49)
Hyaluronic acid 0.81 (0.74-0.89) 0.80 (0.70-0.90)
Collagen IV 0.77 (0.69-0.85) 0.75 (0.64-0.86)
YKL-40 0.71 (0.62-0.79) 0.67 (0.56-0.78)
MMP-9 0.71 (0.63-0.80) 0.68 (0.57-0.80)
MMP-2 0.71 (0.62-0.79) 0.64 (0.53-0.76)
PIIINP 0.67 (0.58-0.77) 0.69 (0.57-0.81)
TIMP-1 0.63 (0.55-0.72) 0.61 (0.50-0.72)
AAR 0.62 (0.53-0.71) 0.56 (0.45-0.68)
PGA 0.62 (0.52-0.73) 0.70 (0.57-0.84)
PGAA 0.75 (0.66-0.84) 0.81 (0.70-0.91)
FFI 0.79 (0.72-0.88) 0.83 (0.73-0.92)
APRI 0.76 (0.68-0.84) 0.76 (0.66-0.87)
CDS 0.62 (0.53-0.71) 0.65 (0.53-0.77)
API 0.77 (0.69-0.85) 0.77 (0.67-0.86)
Table 4. AUROC (95% CI) of various markers or models in pre-
dicting significant liver fibrosis (≥F2)(Fig. 2). The AUROC for ≥F2 on the AHH index was 0.91
(95% confidence interval [CI], 0.85-0.96; P<0.001), which
was significantly higher than that of single serum markers
like hyaluronic acid, haptoglobin, collagen IV, and a2-macro-
globulin, as well as those of previously-reported fibrosis pre-
diction models like the PGAA index, FFI, APRI, and API.
Furthermore, the AHH index also showed relatively good
accuracy for predicting ≥F3 and F4 with AUROCs for ≥F3
and F4 of 0.82 (95% CI, 0.75-0.89) and 0.81 (95% CI, 0.73-
0.89), respectively. Predictive efficacies of the AHH index
for detecting significant liver fibrosis (≥F2) with various
cutoff values are shown in Table 8. Using the cutoff value of
5, the AHH index demonstrated an 89% sensitivity, 78%
specificity, 89% positive predictive value, and 78% nega-
tive predictive value in predicting ≥F2. The ROC curve of
the AHH index is presented in Fig. 3.
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AST, aspartate aminotransferase; ALT, alanine aminotransferase; g-GT,
gamma-glutamyl transpeptidase; PIIINP, procollagen III N-terminal pep-
tide; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metallo-
proteinase.
Fibrosis stage
P value
F0-1 (n=52)
Variables
F2-4 (n=106)
Age (yr) 34±14 44±12 <0.001
BMI (kg/m
2) 24.4±3.9 23.7±3.1 NS
Platelet (×10
3/mL) 213.3±59.9 171.8±73.7 0.001
Prothrombin time (%) 102.1±15.7 92.8±22.9 0.02
AST (IU/L) 52.3±39.8 125.9±199.8 <0.001
ALT (IU/L) 91.6±94.2 170.5±267.9 0.008
g-GT (IU/L) 60.0±50.8 111.1±167.3 0.005
Cholesterol (mg/dL) 169.3±32.2 160.7±30.5 NS
Apolipoprotein A1 (mg/dL) 136.3±23.4 132.7±26.0 NS
a2-macroglobulin (mg/dL) 178.1±50.5 249.0±87.8 <0.001
Haptoglobin (mg/dL) 93.0±55.0 42.1±38.2 <0.001
PIIINP (U/mL) 3.2±14.6 1.3±0.5 NS
Collagen IV (ng/mL) 116.9±46.2 211.5±235.6 <0.001
Hyaluronic acid (ng/mL) 26.1±29.3 112.1±151.2 <0.001
MMP-2 (ng/mL) 220.3±58.8 270.2±79.6 <0.001
MMP-9 (ng/mL) 578.6±298.2 384.1±231.9 <0.001
TIMP-1 (ng/mL) 132.7±31.3 173.1±89.8 <0.001
YKL-40 (ng/mL) 96.2±62.9 158.7±88.9 <0.001
Table 5. Univariate analysis for the variables associated with sig-
nificant liver fibrosis (≥F2)
Regression
coefficient
Odds
ratio
P value
95% CI for
odds ratio
Hyaluronic acid  0.033 1.033 0.964-0.995 0.017
(ng/mL)
a2-macroglobulin 0.017 1.017 1.006-1.061 0.002
(mg/dL)
Haptoglobin -0.025 0.976 0.962-0.990 0.001
(mg/dL)
Table 6. Multiple logistic regression analysis for the variables
showing an independent relationship with significant liver fibrosis
AHH score is the sum of the scores of three variables.
Scores Variables
a2-macroglobulin (mg/dL) ≤150=0 151-250=1 >250=3
Hyaluronic acid (ng/mL) ≤15=0 16-60=2 >60=3
Haptoglobin (mg/dL) ≤45=3 46-100=2 >100=0
Table 7. New scoring system (AHH index) for the prediction of
significant liver fibrosis
PPV, positive predictive value; NPV, negative predictive value.
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
AHH
≥3 98.9 39.1 76.1 94.7
≥5 88.9 78.3 88.9 78.3
≥6 75.6 91.3 94.4 65.6
≥8 37.8 97.8 97.1 44.6
Table 8. Diagnostic accuracy of AHH in predicting significant
liver fibrosis using various cutoff values
Fig. 2. AHH index according to significant liver fibrosis. 
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Fig. 3. ROC curve of the AHH index for the prediction of signifi-
cant liver fibrosis: F0-1 vs. F2-4.
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VariablesDISCUSSION
In the management of chronic liver disease, it is clinically
important to assess the progression of liver fibrosis. Further-
more, with recent improvements in treatment modalities for
chronic liver disease, there is an increasing need for accurate
noninvasive methods, such as surrogate blood markers, which
enable repetitive measurement of the degree of liver fibrosis.
In order for these blood markers to be utilized as accurate pre-
dictors of the degree of liver fibrosis, 1) they should reflect
the specific changes in the liver during the progression of fibro-
sis, 2) they should be sensitive both to fibrogenesis and fibrol-
ysis, 3) their metabolic pathways should be defined, and their
blood levels and half-life should not be influenced by the func-
tion of the liver, kidney, or reticuloendothelial system, and
4) they should be easily measured. However, it is not easy to
find a marker that fulfills all these criteria (18, 19).
Liver fibrosis results from accumulation of ECM as a conse-
quence of chronic liver injury, leading to architectural changes
in the liver parenchyma that eventually cause liver dysfunc-
tion and portal hypertension. Therefore, both direct markers,
such as components of ECM itself or factors that are involved
in the synthesis or degradation of ECM, and indirect mark-
ers influenced by liver injury, altered liver function, or por-
tal hypertension are all potential markers for predicting the
stages of liver fibrosis. For examples, as indirect markers, AST,
ALT, and g-GT reflect liver injury; prothrombin time, choles-
terol, haptoglobin, and a2-macroglobulin reflect altered liver
function caused by architectural changes; platelet counts are
closely related with portal hypertension. Collagen, glycopro-
tein, and proteoglycan, which are components of the ECM,
have drawn attention as potential direct markers. Accumula-
tion of these ECM components could be caused not only by
an increase in their synthesis, but also by a decrease in their
degradation, which might be caused by over-stimulation of
the expression of tissue inhibitor of metalloproteinase (26, 27).
Most studies related to blood markers predicting liver fibro-
sis have been performed in Western patients with chronic
hepatitis C, and it is unknown if their findings can be applied
directly to the Asian people. Furthermore, most previous stud-
ies have focused on 1 or 2 potential markers predictive of liver
fibrosis. Thus, few large comparative studies investigating
the majority of these direct and indirect fibrosis markers have
been performed. In this study, we included most previously-
known direct or indirect potential markers of liver fibrosis
and tried to determine if they could also be used in Korean
patients, in whom chronic hepatitis B is the main cause of
chronic liver disease.
We found that various direct and indirect blood markers
known as useful predictors of liver fibrosis in previous West-
ern studies were also valuable in Korean patients. In partic-
ular, a2-macroglobulin, haptoglobin, and hyaluronic acid
were independent factors predictive of significant liver fibro-
sis on multivariate regression analysis. a2-macroglobulin and
haptoglobin, the two major components of a2-globulin, are
synthesized in hepatocytes, but a2-macroglobulin is also syn-
thesized in hepatic stellate cells. Generally, a2-macroglobu-
lin is an acute-phase protein, and its synthesis increases with
the activation of hepatic stellate cells in inflammatory con-
dition and may precipitate liver fibrosis via its inhibition of
collagenase (1). Previous studies have already reported that
haptoglobin has a negative correlation with the progression
of liver fibrosis independent of hemolysis, hypersplenism, or
liver failure (16, 28). It has also been suggested that hapto-
globin might be related to the growth factors that vary with
the progression of liver fibrosis (16). In the present study,
hyaluronic acid showed the highest AUROC for predicting
≥F2 among the various single fibrosis markers studied, and
its AUROC was superior to those of pre-existing liver fibrosis
prediction models such as PGAA, FFI, APRI, and API. The
increase in hyaluronic acid in chronic liver disease is caused by
increased synthesis by hepatic stellate cells and by a decrease
in uptake and degradation by sinusoidal cells. Our results were
consistent with previous reports suggesting the usefulness
of hyaluronic acid as a liver fibrosis marker (29, 30).
Finally, we constructed the AHH index for the prediction
of significant fibrosis with these three independent predic-
tive markers: a2-macroglobulin, haptoglobin, and hyaluron-
ic acid. The AUROC for predicting ≥F2 of the AHH index
was 0.91, which is superior to the AUROCs of the PGA in-
dex, PGAA index, FFI, APRI, and API. These results sug-
gest that the AHH index could be a good model for predict-
ing significant fibrosis in Korean patients with chronic liver
disease. Further validation studies are needed to evaluate the
predictive efficacy of the AHH index.
In conclusion, a2-macroglobulin, haptoglobin, and hya-
luronic acid were independent factors for predicting signifi-
cant liver fibrosis in our patients with chronic liver disease.
These markers enabled us to establish a new predictive model
useful for detecting significant liver fibrosis. 
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